Beam Therapeutics vs Vivtex

Side-by-side comparison of AI visibility scores, market position, and capabilities

Vivtex leads in AI visibility (68 vs 38)
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile
Vivtex logo

Vivtex

ChallengerBioTech

Oral Biologics Drug Delivery

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

AI VisibilityBeta
Overall Score
B68
Category Rank
#1 of 1
AI Consensus
83%
Trend
up
Per Platform
ChatGPT
66
Perplexity
63
Gemini
63

About

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

Full profile

AI Visibility Head-to-Head

38
Overall Score
68
#1
Category Rank
#1
64
AI Consensus
83
up
Trend
up
44
ChatGPT
66
34
Perplexity
63
29
Gemini
63
30
Claude
60
34
Grok
67

Key Details

Category
Base Editing Gene Therapy
Oral Biologics Drug Delivery
Tier
Growth
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Beam Therapeutics
Base Editing Gene Therapy
Only Vivtex
Oral Biologics Drug Delivery

Integrations

Only Vivtex

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.